The estimated Net Worth of John J Monahan is at least $157 Thousand dollars as of 29 April 2019. John Monahan owns over 900 units of Anixa Biosciences stock worth over $157,281 and over the last 11 years he sold ANIX stock worth over $0. In addition, he makes $0 as Independent Director at Anixa Biosciences.
John has made over 1 trades of the Anixa Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 900 units of ANIX stock worth $3,798 on 29 April 2019.
The largest trade he's ever made was buying 900 units of Anixa Biosciences stock on 29 April 2019 worth over $3,798. On average, John trades about 43 units every 0 days since 2013. As of 29 April 2019 he still owns at least 50,900 units of Anixa Biosciences stock.
You can see the complete history of John Monahan stock trades at the bottom of the page.
Dr. John Monahan Ph.D. serves as Independent Director of the Company. He is an experienced executive and has served on a number of biotechnology company boards over the years. He is currently a Scientific Advisory Consultant for Synthetic Biologics, Inc., a publicly traded biotechnology company, and from 2010 through 2015 he was the Senior Executive Vice President of Research & Development at Synthetic Biologics, Inc. He is also a director of Heat Biologics, Inc., a publicly traded biotechnology company, a position that he has held since 2011, and was a director of Tacere Therapeutics, Inc., a privately held biotechnology company, from 2006 to 2012. In addition to his work with public companies, Dr. Monahan is also currently a member of the Scientific Advisory Board of Agilis Biotherapeutics, Inc., a position that he has held since 2014, and is a board member of several other biotechnology companies. In 1992 he founded Avigen, Inc., a biotechnology company that pioneered the development of gene medicines based on adeno-associated virus vectors, now an industry standard. Over a 12-year period as its Chief Executive Officer, Dr. Monahan took Avigen public through an initial public offering raising over $235 million and led the company through several IND applications. Prior to Avigen, Dr. Monahan served as Vice President - Research and Development at Somatix B.V., and Director of Molecular & Cell Biology at Triton Biosciences, Inc. He was also previously Research Group Chief, Department of Molecular Genetics at Hoffmann-LaRoche Inc., and Adjunct Assistant Professor, Department of Cell Biology at New York University. Dr. Monahan earned a Ph.D. in Biochemistry from McMaster University, Hamilton, Canada, and a B.S. in Science from University College, Dublin, Ireland. Dr. Monahan has over 50 publications in scientific literature and has made hundreds of presentations and public TV appearances, to scientific groups, investors and the general public over the years.
John Monahan is 73, he's been the Independent Director of Anixa Biosciences since 2016. There are 1 older and 9 younger executives at Anixa Biosciences. The oldest executive at Anixa Biosciences, Inc. is Lewis Titterton, 75, who is the Lead Independent Director.
John's mailing address filed with the SEC is C/O HEAT BIOLOGICS, INC., 627 DAVIS DRIVE, MORRISVILLE, NC, 27560.
Over the last 6 years, insiders at Anixa Biosciences have traded over $0 worth of Anixa Biosciences stock and bought 834,156 units worth $2,822,805 . The most active insiders traders include Amit Kumar, Lewis H Jr Titterton, and Arnold M Baskies. On average, Anixa Biosciences executives and independent directors trade stock every 31 days with the average trade being worth of $78,894. The most recent stock trade was executed by Lewis H Jr Titterton on 30 July 2024, trading 27,226 units of ANIX stock currently worth $84,128.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Anixa Biosciences executives and other stock owners filed with the SEC include: